Reduced-intensity chemo and radiation before a donor bone marrow transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a lower-intensity chemotherapy and radiation plan before getting a bone marrow (stem cell) transplant from a related donor. It’s meant for people with blood cancers who are considered at higher risk of relapse with standard lower-intensity treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a related donor matched well enough (3 out of 6 to 5 out of 6 matches) and the donor test does not show an incompatible response in the transplant direction
- You can have your performance/strength level assessed and score 70% or higher
- You have a blood cancer where your doctors expect a high risk of relapse with less intense (non-myeloablative) treatment before transplant
- Your heart pumping function is strong enough (LVEF 45% or higher)
- Your lungs work well enough (FEV, FVC, and lung DLCO are all 60% or higher)
- Your liver and kidneys function are strong enough (bilirubin below 2.5, AST/ALT not more than 3 times normal, and kidney filtration 40 mL/min or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
This study tests a less intense chemotherapy conditioning regimen before a stem cell transplant in people with myelodysplastic syndromes (MDS), a type of blood cancer where the bone marrow doesn't make enough healthy blood cells. The aim is to see if this approach is safer and still works well, potentially helping more people qualify for transplant.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.